There’s no denying that every CML patient’s desire is to one day graduate from the burden of maintenance and affordability that the daily treatment of TKI’s (oral chemotherapy) represent. In this video, worldwide CML experts Dr. Meir Wetzler, Dr. Jorge Cortes, and Dr. Moshe Talpaz, along with our own Greg Stephens bring you the latest information regarding the viability of a potential stop in treatment, the STIM trial, and the development of combination therapy. Special thanks to our friends at Patient Power for their outstanding advocacy.
Newly diagnosed patients see patients that have been under treatment for many years and in deep levels of response and they’re really excited about this, as they should be. The newly diagnosed patient has a job before them that has to be done first.
– Greg Stephens, CEO The National CML Society